Cumberland Pharmaceuticals CPIX Operating lease liabilities

Operating lease liabilities at other companies

PTH

Pelthos Therapeutics Inc.PTHS

——

Rigel PharmaceuticalsRIGL

——

BridgeBio PharmaBBIO

——

Mirum Pharmaceuticals, Inc.MIRM

——

Other financials

Income statement

See full

Revenue$9.1M-22.0%

Gross profit$7.2M-30.0%

Operating income-$3.1M-342%

Net income-$3.3M-362%

EPS (diluted)-$0.22-375%

Balance sheet

See full

Cash & equivalents$11.0M-27.1%

Total debt$4.8M-7.1%

Total equity$21.6M-24.5%

Total assets$71.0M+1.5%

Cash flow

See full

Operating cash flow$387.0K-90.1%

CapEx--100%

Free cash flow$387.0K-89.9%

Valuation

See full

Market cap$97.09M+142%

Enterprise value$90.91M+212%

P/S2.3×+1.4×

Profitability

See full

Gross margin82.9%-1.4pp

Operating margin-17.2%-125pp

Net margin-17.6%-103pp

FCF margin3.3%—

Returns & leverage

See full

Return on equity-29.4%-86.3pp

Debt / equity0.2×0.0×

Current ratio1×-0.3×

Where this comes from

Reported directly by Cumberland Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Cumberland Pharmaceuticals's operating lease liabilities?: Cumberland Pharmaceuticals (CPIX) reported operating lease liabilities of -$225.35K in Q1 2026.
How has Cumberland Pharmaceuticals's operating lease liabilities changed year-over-year?: Cumberland Pharmaceuticals's operating lease liabilities decreased by 2.7% year-over-year, from -$219.49K to -$225.35K.